Phio Pharmaceuticals Corp... (PHIO)
1.41
-0.02 (-1.40%)
At close: Feb 28, 2025, 3:59 PM
1.42
0.71%
After-hours: Feb 28, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 1.39 |
| Market Cap | 6.74M |
| Revenue (ttm) | 144.75K |
| Net Income (ttm) | -35.8M |
| EPS (ttm) | -9.75 |
| PE Ratio (ttm) | -0.14 |
| Forward PE | 0.07 |
| Analyst | Buy |
| Ask | 1.43 |
| Volume | 91,688 |
| Avg. Volume (20D) | 6,575,123 |
| Open | 1.45 |
| Previous Close | 1.43 |
| Day's Range | 1.36 - 1.43 |
| 52-Week Range | 1.36 - 10.35 |
| Beta | 1.53 |
About PHIO
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic pr...
Industry Biotechnology
Sector Healthcare
IPO Date May 10, 2012
Employees 8
Stock Exchange NASDAQ
Ticker Symbol PHIO
Website https://www.phiopharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for PHIO stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 183.69% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago
-25.7%
Phio Pharmaceuticals shares are trading lower afte...
Unlock content with
Pro Subscription
1 month ago
-45.76%
Phio Pharmaceuticals shares are trading lower after the company announced a $3.19 million registered direct offering.
